MAPT and Alzheimer disease: Our data suggest that the amount of NP tau pathology observed in AD-tau-injected 5XFAD mice is not entirely predicted by the extent of microglial interaction with plaques, nor is development of appreciable tau pathology dependent on the complete loss of a DAM phenotype.